Data gathered: January 14
Alternative Data for Corcept Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 45 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 24,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,017 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 495 | Sign up | Sign up | Sign up |
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
| Price | $51.06 |
| Target Price | Sign up |
| Volume | 590,430 |
| Market Cap | $5.22B |
| Year Range | $25.4 - $60.85 |
| Dividend Yield | 0% |
| PE Ratio | 39.56 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
GAMMA Investing LLC Purchases 506 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)January 10 - ETF Daily News |
|
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $1,007,800.00 in StockJanuary 7 - ETF Daily News |
 |
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased GuidanceJanuary 6 - Yahoo |
 |
Corcept Therapeutics president sells $1 million in stockJanuary 6 - Investing.com |
Latest Published 4 Rare Neurological Disorders Market Reports by DelveInsight: Amyotrophic Lateral Sclerosis, Developmental and Epileptic Encephalopathies, Primary Ciliary Dyskinesia, and Chronic Inflammatory Demyelinating PolyneuropathyJanuary 9 - GlobeNewswire |
|
 |
Discover 3 US Growth Stocks With Strong Insider OwnershipJanuary 6 - Yahoo |
Insider Transactions View All
| Lyon Joseph Douglas filed to sell 8,759 shares at $50.4. January 6 '25 |
| Robb Gary Charles filed to sell 20,119 shares at $50.5. January 6 '25 |
| Maduck Sean filed to sell 85,318 shares at $50.4. January 6 '25 |
| Lyon Joseph Douglas filed to sell 8,494 shares at $56.7. November 26 '24 |
Similar companies
Read more about Corcept Therapeutics (CORT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Corcept Therapeutics?
The Market Cap of Corcept Therapeutics is $5.22B.
What is Corcept Therapeutics' PE Ratio?
As of today, Corcept Therapeutics' PE (Price to Earnings) ratio is 39.56.
What is the current stock price of Corcept Therapeutics?
Currently, the price of one share of Corcept Therapeutics stock is $51.06.
How can I analyze the CORT stock price chart for investment decisions?
The CORT stock price chart above provides a comprehensive visual representation of Corcept Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Corcept Therapeutics shares. Our platform offers an up-to-date CORT stock price chart, along with technical data analysis and alternative data insights.
Does CORT offer dividends to its shareholders?
As of our latest update, Corcept Therapeutics (CORT) does not offer dividends to its shareholders. Investors interested in Corcept Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Corcept Therapeutics?
Some of the similar stocks of Corcept Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.